Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Enzyme replacement therapy approvals hinge on three things: confirmed diagnostic proof, documented medical necessity, and a prescriber who anticipates payer requirements before submitting. There are several factors to consider. See below to understand more.
Most denials trace back to missing enzyme assay or genetic testing results, incomplete prior authorization forms, or infusion sites that fall outside a plan's network, so gathering biochemical confirmation, specialist notes, and baseline clinical measures early prevents weeks of delay. When coverage is denied, patients have the right to appeal, request a peer-to-peer review between the prescriber and the plan's medical director, and escalate to an external independent review, while manufacturer patient assistance programs, nonprofit copay foundations, and hospital financial counselors can bridge costs during that window. Because these therapies often run into six figures annually, understanding your plan's specialty pharmacy rules, annual out-of-pocket maximum, and site-of-care policies matters as much as the clinical paperwork.
If symptoms are still unexplained or you are unsure whether a metabolic or lysosomal storage condition could be behind them, a free, instant, online symptom check can help you organize what you are experiencing into clear, shareable language that speeds up specialist referrals and strengthens the documentation your approval depends on.
Last reviewed for medical accuracy: 08/18/2026
Enzyme replacement therapies (ERTs) like Strensiq® offer life-changing benefits for people with rare genetic disorders, but navigating the financial and insurance hurdles can feel overwhelming. This guide breaks down key steps, cost considerations, and resources for Strensiq cost and insurance coverage assistance—so you can focus on your health, not paperwork.
Strensiq (asfotase alfa) treats hypophosphatasia, a rare metabolic condition. By replacing a missing enzyme, it:
Because it’s a specialized biologic, Strensiq’s list price can exceed $500,000 per year. However, most patients pay far less with insurance and financial assistance.
When you start considering Strensiq, it helps to know:
List price vs. out-of-pocket
– The manufacturer’s list price: ~$600,000 annually (varies by dose/weight)
– Typical patient out-of-pocket: $0–$10,000 yearly, depending on insurance
Insurance coverage landscape
– Private commercial plans often require prior authorization
– Medicare Part B may cover therapy administered in a clinic
– Medicaid coverage varies by state
Role of specialty pharmacies
– Providers like Accredo or BioPlus can handle authorizations, shipping and billing
– They coordinate with your doctor and insurer on dosing and paperwork
Diagnosis and Documentation
Physician Prescription & Prior Authorization
Insurance Review
Approval, Denial, or Request for More Information
Appeals Process (if needed)
Know your plan details
Engage a financial navigator
Coordinate multiple insurance sources
Alexion Pharmaceuticals (Strensiq’s manufacturer) provides:
Keep a dedicated folder (paper or digital) with:
Set reminders for:
Ask your specialty pharmacy or hospital to assign a financial counselor. They can:
It’s easy to feel overwhelmed when fighting for insurance approval and financial aid. To stay on top of your health (and paperwork):
You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to monitor new or changing symptoms and share results with your care team. (https://ubiehealth.com/)
If you experience any of the following, seek medical attention immediately:
Always discuss serious or life-threatening issues with your physician without delay.
Navigating Strensiq cost and insurance coverage assistance takes persistence and support. By understanding your insurance plan, leveraging manufacturer programs, and tapping into nonprofit resources, you can minimize out-of-pocket expenses and focus on treatment. Keep thorough records, meet deadlines, and enlist a financial navigator to guide you through renewals and appeals. With the right team and tools, accessing enzyme replacement therapy becomes a structured process rather than an endless obstacle.
Remember to speak to a doctor about any serious health concerns—your well-being always comes first.
(References)
* van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008 Oct 11;372(9646):1342-53. doi: 10.1016/S0140-6736(08)61555-X. PMID: 18929906.
* Pastores GM, Gupta P. Orphan drug development. Pediatr Endocrinol Rev. 2013 Nov;11 Suppl 1:64-7. PMID: 24380124.
* Markham A. Cerliponase Alfa: First Global Approval. Drugs. 2017 Jul;77(11):1247-1249. doi: 10.1007/s40265-017-0771-8. PMID: 28589525.
* Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018 May;55(5):351-358. doi: 10.1136/jmedgenet-2017-104863. Epub 2018 Feb 7. PMID: 29437868; PMCID: PMC5931248.
* Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, Elliott PM, Hagege A, Kuusisto J, Linhart A, Nordbeck P, Olivotto I, Pietilä-Effati P, Namdar M. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Feb 23;77(7):922-936. doi: 10.1016/j.jacc.2020.12.024. PMID: 33602475.
* Keam SJ. Olipudase Alfa: First Approval. Drugs. 2022 Jun;82(8):941-947. doi: 10.1007/s40265-022-01727-x. PMID: 35639287.
* Schlesinger N, Pérez-Ruiz F, Lioté F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023 Oct;19(10):640-649. doi: 10.1038/s41584-023-01006-3. Epub 2023 Sep 8. PMID: 37684360.
* Colella P. Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy. Mol Diagn Ther. 2024 Nov;28(6):703-719. doi: 10.1007/s40291-024-00733-x. Epub 2024 Aug 12. PMID: 39134822.
* George KA, Anding AL, van der Flier A, Tomassy GS, Berger KI, Zhang TY, Sardi SP. Pompe disease: Unmet needs and emerging therapies. Mol Genet Metab. 2024 Nov;143(3):108590. doi: 10.1016/j.ymgme.2024.108590. Epub 2024 Oct 11. PMID: 39418752.
* Iglesia D, Vujasinovic M, Löhr JM, Dominguez-Muñoz JE. Pancreatic exocrine insufficiency. EClinicalMedicine. 2026 Apr;94:103880. doi: 10.1016/j.eclinm.2026.103880. Epub 2026 Apr 11. PMID: 42011215; PMCID: PMC13091941.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.